Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 5Unknown 2Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 1Hepatitis 1Chemical and Drug Induced Liver Injury 1Adenomatous Polyposis Coli 1Adenoma 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Ursodeoxycholic Acid × Clear all
NCT04810156 2022-12-14

I-HEP

Herlev Hospital

Phase 2 Unknown
60 enrolled

Hepatitis, Neoplasms, Chemical and Drug Induced Liver Injury

NCT00134758 2009-07-29

Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Unknown
90 enrolled
Gastrointestinal

Adenoma, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡